|
May 17
|
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
|
|
Apr 7
|
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
|
|
Jan 9
|
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
|